11-72822145-C-A
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The ENST00000321297.10(ATG16L2):c.494C>A(p.Ala165Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000247 in 1,499,572 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Consequence
ENST00000321297.10 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ATG16L2 | NM_033388.2 | c.494C>A | p.Ala165Glu | missense_variant | 5/18 | ENST00000321297.10 | NP_203746.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ATG16L2 | ENST00000321297.10 | c.494C>A | p.Ala165Glu | missense_variant | 5/18 | 1 | NM_033388.2 | ENSP00000326340 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152064Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000671 AC: 6AN: 89380Hom.: 0 AF XY: 0.0000992 AC XY: 5AN XY: 50426
GnomAD4 exome AF: 0.0000245 AC: 33AN: 1347508Hom.: 0 Cov.: 33 AF XY: 0.0000241 AC XY: 16AN XY: 664526
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152064Hom.: 0 Cov.: 33 AF XY: 0.0000269 AC XY: 2AN XY: 74286
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 25, 2023 | The c.494C>A (p.A165E) alteration is located in exon 5 (coding exon 5) of the ATG16L2 gene. This alteration results from a C to A substitution at nucleotide position 494, causing the alanine (A) at amino acid position 165 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at